The Claim
In patients with coronary artery disease, adding ezetimibe, bempedoic acid, or PCSK-9 inhibitors to statin therapy does not significantly reduce all-cause mortality, regardless of whether the treatment duration is less than or at least 3 years, indicating that intensified lipid-lowering strategies do not confer a survival benefit despite reducing cardiovascular events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Even if you add extra cholesterol drugs like ezetimibe, bempedoic acid, or PCSK-9 inhibitors to statins, people with heart disease don’t live longer — it helps prevent heart attacks, but doesn’t seem to help them survive overall.
See the scientific wording
Adding ezetimibe, bempedoic acid, or PCSK-9 inhibitors to statin therapy in patients with coronary artery disease does not reduce all-cause mortality, with no significant difference observed regardless of whether follow-up duration was less than or at least 3 years, indicating that despite cardiovascular event reduction, survival benefit is not achieved with intensified lipid-lowering strategies.
What the research says
1 studyStudy: Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
The study found that adding certain cholesterol drugs to statins helps prevent heart attacks and strokes but doesn’t help people live longer, no matter how long they take them.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.